Claudia Kuntner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5261787/publications.pdf

Version: 2024-02-01

79	2,192	236833	243529
papers	citations	25 h-index	44 g-index

83	83	83	2481
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Use of PET Imaging to Assess the Efficacy of Thiethylperazine to Stimulate Cerebral MRP1 Transport Activity in Wild-Type and APP/PS1-21 Mice. International Journal of Molecular Sciences, 2022, 23, 6514.	1.8	2
2	Medical Physics and Imagingâ€“A Timely Perspective. Frontiers in Physics, 2021, 9, .	1.0	5
3	Assessing the Functional Redundancy between P-gp and BCRP in Controlling the Brain Distribution and Biliary Excretion of Dual Substrates with PET Imaging in Mice. Pharmaceutics, 2021, 13, 1286.	2.0	7
4	Characterization of an APP/tau rat model of Alzheimerâ€™s disease by positron emission tomography and immunofluorescent labeling. Alzheimer's Research and Therapy, 2021, 13, 175.	3.0	8
5	Measurement of cerebral ABCC1 transport activity in wild-type and APP/PS1-21 mice with positron emission tomography. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 954-965.	2.4	14
6	Vitamin K3 chloro derivative (VKT-2) inhibits HDAC6, activates autophagy and apoptosis, and inhibits aggresome formation in hepatocellular carcinoma cells. Biochemical Pharmacology, 2020, 180, 114176.	2.0	11
7	Editorial: Status Go for Preclinical Imaging. Frontiers in Physics, 2020, 8, .	1.0	0
8	Impact of Attenuation Correction on Quantification Accuracy in Preclinical Whole-Body PET Images. Frontiers in Physics, 2020, 8, .	1.0	0
9	Plasma pharmacokinetic and metabolism of [18F]THK-5317 are dependent on sex. Nuclear Medicine and Biology, 2020, 84-85, 28-32.	0.3	5
10	Real-time data-driven motion correction in PET. EJNMMI Physics, 2019, 6, 3.	1.3	10
11	Reproducibility and Comparability of Preclinical PET Imaging Data: A Multicenter Small-Animal PET Study. Journal of Nuclear Medicine, 2019, 60, 1483-1491.	2.8	20
12	Influence of Multidrug Resistance-Associated Proteins on the Excretion of the ABCC1 Imaging Probe 6-Bromo-7-[11C]Methylpurine in Mice. Molecular Imaging and Biology, 2019, 21, 306-316.	1.3	15
13	Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice. European Journal of Pharmaceutical Sciences, 2018, 115, 212-222.	1.9	4
14	[18F]Fluoroalkyl azides for rapid radiolabeling and (Re)investigation of their potential towards in vivo click chemistry. Organic and Biomolecular Chemistry, 2017, 15, 5976-5982.	1.5	13
15	Guidance for Efficient Small Animal Imaging Quality Control. Molecular Imaging and Biology, 2017, 19, 485-498.	1.3	24
16	On the applicability of [18F]FBPA to predict L-BPA concentration after amino acid preloading in HuH-7 liver tumor model and the implication for liver boron neutron capture therapy. Nuclear Medicine and Biology, 2017, 44, 83-89.	0.3	14
17	[11 C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice. Nuclear Medicine and Biology, 2017, 52, 7-15.	0.3	6
18	32nd International Austrian Winter Symposium. EJNMMI Research, 2016, 6, 32.	1.1	0

#	Article	IF	Citations
19	Synthesis and preclinical characterization of 1-(6â€²-deoxy-6â€²-[18 F]fluoro-Î²- d) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 747 T assess tumor hypoxia. Bioorganic and Medicinal Chemistry, 2016, 24, 5326-5339.	1.4	13
20	Preloading with L-BPA, L-tyrosine and L-DOPA enhances the uptake of [18F]FBPA in human and mouse tumour cell lines. Applied Radiation and Isotopes, 2016, 118, 67-72.	0.7	12
21	Design, Synthesis, and Evaluation of a Low-Molecular-Weight ¹¹C-Labeled Tetrazine for Pretargeted PET Imaging Applying Bioorthogonal in Vivo Click Chemistry. Bioconjugate Chemistry, 2016, 27, 1707-1712.	1.8	73
22	Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [18F]Ciprofloxacin, a Positron Emission Tomography Study in Mice. Journal of Pharmaceutical Sciences, 2016, 105, 106-112.	1.6	5
23	[18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 741-749.	3.3	5
24	Factors Governing P-Glycoprotein-Mediated Drugâ€“Drug Interactions at the Bloodâ€“Brain Barrier Measured with Positron Emission Tomography. Molecular Pharmaceutics, 2015, 12, 3214-3225.	2.3	39
25	[18F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent bloodâ€“brain barrier. Nuclear Medicine and Biology, 2015, 42, 585-589.	0.3	2
26	Development of Fluorine-18 Labeled Metabolically Activated Tracers for Imaging of Drug Efflux Transporters with Positron Emission Tomography. Journal of Medicinal Chemistry, 2015, 58, 6058-6080.	2.9	18
27	Automated electrophilic radiosynthesis of [18F]FBPA using a modified nucleophilic GE TRACERlab FXFDG. Applied Radiation and Isotopes, 2015, 104, 124-127.	0.7	9
28	Development and performance test of an online blood sampling system for determination of the arterial input function in rats. EJNMMI Physics, 2015, 2, 1.	1.3	22
29	Automated radiosynthesis of [18F]ciprofloxacin. Applied Radiation and Isotopes, 2015, 99, 133-137.	0.7	5
30	Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of ¹¹C-Erlotinib. Journal of Nuclear Medicine, 2015, 56, 1930-1936.	2.8	52
31	Quantitative preclinical PET imaging: opportunities and challenges. Frontiers in Physics, 2014, 2, .	1.0	55
32	Development of a ¹⁸Fâ€Labeled Tetrazine with Favorable Pharmacokinetics for Bioorthogonal PET Imaging. Angewandte Chemie - International Edition, 2014, 53, 9655-9659.	7.2	108
33	Radiosynthesis of [124I]Iodometomidate and Biological Evaluation Using Small-Animal PET. Molecular Imaging and Biology, 2014, 16, 317-321.	1.3	5
34	Kinetic modeling in pre-clinical positron emission tomography. Zeitschrift Fur Medizinische Physik, 2014, 24, 274-285.	0.6	16
35	Preclinical in vitro & in vivo evaluation of [11C]SNAP-7941 â€“ the first PET tracer for the melanin concentrating hormone receptor 1. Nuclear Medicine and Biology, 2013, 40, 919-925.	0.3	20
36	(R)-[11C]verapamil is selectively transported by murine and human P-glycoprotein at the bloodâ€“brain barrier, and not by MRP1 and BCRP. Nuclear Medicine and Biology, 2013, 40, 873-878.	0.3	67

#	Article	IF	Citations
37	Tariquidar and Elacridar Are Dose-Dependently Transported by P-Glycoprotein and Bcrp at the Blood-Brain Barrier: A Small-Animal Positron Emission Tomography and In Vitro Study. Drug Metabolism and Disposition, 2013, 41, 754-762.	1.7	79
38	Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats. Nuclear Medicine and Biology, 2013, 40, 755-763.	0.3	15
39	Guidance for Methods Descriptions Used in Preclinical Imaging Papers. Molecular Imaging, 2013, 12, 7290.2013.00055.	0.7	23
40	18F, 11C and 68Ga in small animal PET imaging. Nuklearmedizin - NuclearMedicine, 2013, 52, 250-261.	0.3	5
41	A Novel PET Protocol for Visualization of Breast Cancer Resistance Protein Function at the Bloodâ€“Brain Barrier. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 2002-2011.	2.4	46
42	Interaction of HM30181 with P-glycoprotein at the murine bloodâ€“brain barrier assessed with positron emission tomography. European Journal of Pharmacology, 2012, 696, 18-27.	1.7	9
43	Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [11C]MC113. Nuclear Medicine and Biology, 2012, 39, 1219-1225.	0.3	17
44	Pgp-Mediated Interaction Between (R)-[11C]Verapamil and Tariquidar at the Human Bloodâ€“Brain Barrier: A Comparison With Rat Data. Clinical Pharmacology and Therapeutics, 2012, 91, 227-233.	2.3	108
45	Pharmacokinetic modeling of P-glycoprotein function at the rat and human bloodâ€“brain barriers studied with (R)-[11C]verapamil positron emission tomography. EJNMMI Research, 2012, 2, 58.	1.1	16
46	The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the bloodâ€“brain barrier: A positron emission tomography study. Epilepsy Research, 2012, 100, 93-103.	0.8	12
47	A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 149-159.	3.3	23
48	Radiosynthesis and Assessment of Ocular Pharmacokinetics of 124I-Labeled Chitosan in Rabbits Using Small-Animal PET. Molecular Imaging and Biology, 2011, 13, 222-226.	1.3	19
49	Inhibition of breast cancer resistance protein at the murine blood-brain barrier by Ko143 studied with [11C]tariquidar and PET. BMC Pharmacology, 2011, 11, .	0.4	1
50	Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein. Bioorganic and Medicinal Chemistry, 2011, 19, 2190-2198.	1.4	30
51	Gastric Cancer Growth Control by BEZ235In VivoDoes Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake. Clinical Cancer Research, 2011, 17, 5322-5332.	3.2	33
52	A Novel Positron Emission Tomography Imaging Protocol Identifies Seizure-Induced Regional Overactivity of P-Glycoprotein at the Blood-Brain Barrier. Journal of Neuroscience, 2011, 31, 8803-8811.	1.7	58
53	A new fast and fully automated software based algorithm for extracting respiratory signal from raw PET data and its comparison to other methods. Medical Physics, 2010, 37, 5550-5559.	1.6	79
54	Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11C]verapamil PET. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 942-953.	3.3	102

#	Article	IF	Citations
55	Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorganic and Medicinal Chemistry, 2010, 18, 5489-5497.	1.4	73
56	BEZ235 impairs gastric cancer growth by inhibition of PI3K/mTOR in vitro and in vivo. BMC Pharmacology, 2010, 10, .	0.4	1
57	Small-animal PET evaluation of [11C]MC113 as a PET tracer for P-glycoprotein. BMC Pharmacology, 2010, 10, .	0.4	0
58	Assessing cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor [11C]substrate scans. NeuroImage, 2010, 52, S116.	2.1	0
59	Evaluation of [11C]elacridar and [11C]tariquidar in transporter knockout mice using small-animal PET. NeuroImage, 2010, 52, S25.	2.1	3
60	Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate. Nuclear Medicine and Biology, 2010, 37, 637-644.	1.3	12
61	Amyloid PET and MRI in Alzheimers Disease and Mild Cognitive Impairment. Current Alzheimer Research, 2009, 6, 312-319.	0.7	17
62	Multimodality Rodent Imaging Chambers for Use Under Barrier Conditions with Gas Anesthesia. Molecular Imaging and Biology, 2009, 11, 100-106.	1.3	36
63	Limitations of Small Animal PET Imaging with [18F]FDDNP and FDG for Quantitative Studies in a Transgenic Mouse Model of Alzheimerâ€™s Disease. Molecular Imaging and Biology, 2009, 11, 236-240.	1.3	87
64	FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo. British Journal of Cancer, 2009, 100, 1739-1745.	2.9	40
65	Synthesis and Small-Animal Positron Emission Tomography Evaluation of [11C]-Elacridar As a Radiotracer to Assess the Distribution of P-Glycoprotein at the Bloodâ^'Brain Barrier. Journal of Medicinal Chemistry, 2009, 52, 6073-6082.	2.9	71
66	Synthesis of a [¹⁸F]fluorobenzothiazole as potential amyloid imaging agent. Journal of Labelled Compounds and Radiopharmaceuticals, 2008, 51, 137-145.	0.5	14
67	Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Bloodâ€“Brain Barrier Studied with (R)-¹¹C-Verapamil and PET. Journal of Nuclear Medicine, 2008, 49, 1328-1335.	2.8	104
68	Pre vivo, ex vivo and in vivo evaluations of [68Ga]-EDTMP. Nuclear Medicine and Biology, 2007, 34, 391-397.	0.3	37
69	Validation of PET-SORTEO Monte Carlo simulations for the geometries of the MicroPET R4 and Focus 220 PET scanners. Physics in Medicine and Biology, 2007, 52, 4845-4862.	1.6	19
70	In vivo dose finding of tariquidar using (R)-[11C]verapamil Î¼PET. BMC Pharmacology, 2007, 7, .	0.4	0
71	P-Glycoprotein inhibition at the blood-brain barrier visualized with (R)-[11C]verapamil Î¼PET. BMC Pharmacology, 2007, 7, .	0.4	0
72	Development of an optimized LSO/LuYAP phoswich detector head for the Lausanne ClearPET demonstrator. IEEE Transactions on Nuclear Science, 2006, 53, 25-29.	1.2	28

#	Article	IF	Citations
73	The ClearPETâ„¢ project: development of a 2nd generation high-performance small animal PET scanner. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2005, 537, 307-311.	0.7	121
74	Advances in the scintillation performance of LuYAP:Ce single crystals. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2005, 537, 295-301.	0.7	28
75	The ClearPET project. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2004, 527, 171-174.	0.7	31
76	Scintillation properties of mixed LuYAP crystals in view of their use in a small animal PET scanner in phoswich configuration. IEEE Transactions on Nuclear Science, 2003, 50, 1477-1482.	1.2	19
77	Scintillation properties and mechanism in Lu0.8Y0.2AlO3:Ce. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2002, 486, 176-180.	0.7	36
78	Intrinsic energy resolution and light output of the Lu0.7Y0.3AP:Ce scintillator. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2002, 493, 131-136.	0.7	38
79	Development of new mixed LuYAP:Ce crystals for application in a small animal PET scanner with DOI capability. , 0, , .		3